Breakthrough Drug Cuts Dangerous Post-Bariatric Surgery Events by 64%: Phase 2 Trial Results Revealed

Amylyx Presents New Exploratory Analyses From Avexitide Trials - Data Intelligence

In the Phase IIb study, 90mg of avexitide resulted in a 64% least-squares mean decrease in the composite rate of Level 2 and Level 3 hypoglycaemic events in patients. Credit: Namomooyim/Shutterstock. Amylyx Pharmaceuticals has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of the investigational glucagon-like peptide-1 (GLP-1) receptor antagonist, avexitide, for post-bariatric hypoglycaemia (PBH) treatment. The…

Amylyx presents new exploratory analyses from avexitide trials for PBH

Amylyx has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of avexitide for PBH treatment.The post Amylyx presents new exploratory analyses from avexitide trials for PBH appeared first on Clinical Trials Arena.

Amylyx Pharmaceuticals presents new data on Avexitide for post-bariatric hypoglycemia

Amylyx Pharmaceuticals has represented analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Society’s annual meeting (ENDO 2025).In the Phase 2b trial, avexitide 90 mg once daily, the dose being evaluated in the pivotal Phase 3 LUCIDITY trial, led to a 64% least-squ…

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

Open the article to view the coverage from The AI Journal

Breakthrough Drug Cuts Dangerous Post-Bariatric Surgery Events by 64%: Phase 2 Trial Results Revealed

First-in-class GLP-1 antagonist avexitide shows promising results for post-bariatric hypoglycemia. Phase 3 LUCIDITY trial ongoing. See full efficacy data.